EVO

Evotec SE ADR

Evotec SE ADR (EVO) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (C+); its weakest is Profitability (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
C+
Factor Score 2.7 / 5.0
Growth
C-
Factor Score 2.0 / 5.0
Profitability
D+
Factor Score 1.7 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C-
Factor Score 1.9 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA 34.4
Rev Growth YoY -21.7%
Gross Margin 10.7%
Price Return 3M -37.5%
Price Return 12M -51.5%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 0.9
ROE -24.1%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-05 C+ (2.7) C- (2.0) D+ (1.7) C (2.4) C- (1.9) C- (2.1)
2026-08-04 C+ (2.7) C- (2.0) D+ (1.7) C (2.4) C- (1.9) C (2.2)
2026-08-03 C+ (2.7) C (2.3) C (2.2) C (2.4) C- (2.0) C (2.3)
2026-08-02 C+ (2.7) C (2.3) C (2.2) C (2.4) C- (1.9) C (2.3)